PRKAA1 and graft versus host disease: In both major and minor histocompatibility complex (MHC) models of GVHD, transfer of AMPK-dKO T cells increased survival, decreased weight loss, and lowered GVHD clinical scores out to 60 days post-transplant (Figure 1).